lodi 291 online casino games gameplay

lodi 291 online casino games gameplay We have seen our share of political dramas in our lifetime, but Vice President Sara Duterte’s recent actions—laced with reckless threats and melodrama—take the cake. Perhaps from Mary Grace? Lawyer Sara admitted to the criminal act of contracting a hitman for President Bongbong Marcos and his family. This, during a semi-siege at the Batasan Pambansa in defense of her chief of staff Atty. Zuleika Lopez. What have these antics exposed? Not just her disregard for decorum, but more significantly, her desperate attempts to deflect scrutiny from her office’s questionable spending of confidential funds. Her unravelling traces its roots to the unresolved issue of how her Office of the Vice President (OVP) expended P125 million in confidential funds daily in many areas in one day. Public outcry has centered on the flagrant lack of transparency and accountability in this robbery -like operation. The audacious speed and secrecy with which the funds—our money as taxpayers—were withdrawn, disbursed, and liquidated. The fast and furious maneuvers deserve at least one break to snack on Piattos. In this case, there’s no rest for the wicked. Many veteran career officials found the process alarming in its deviation from standard protocols. Duterte and her trusted inner circle, including Lopez, have offered little to assuage the people’s concerns. Instead, they have chosen the path of “bratinella” defiance and obfuscation. The brazenness of these transactions mirrors scenes from a crime thriller. Yet, this is no fictional “Money Heist”—it is a real-life plundering of public funds, a betrayal of trust by an office that not so long ago exemplified integrity. At its core, this is not about Duterte’s politics or her disagreements with the administration. It is about the audacious misuse of power and money meant for the Filipino people. Let’s never forget. Duterte’s profanity-laced tirades and theatrics serve one purpose: to distract us—the public—from the damning revelations being laid bare at the House hearings. Her threats to assassinate President Ferdinand Marcos Jr. and other high-ranking officials, while conditional and couched in dramatic language, are deeply troubling. They showcase a lack of judgment and restraint, but more importantly they also shift attention away from the pressing issue of financial accountability. The Vice President’s continued defense of Lopez adds another layer to this political circus. Her dramatic pledge to accompany Lopez to detention and her fiery attacks on the House’s leadership create a spectacle designed to evoke sympathy while undermining the constitutional principles of checks and balances. But we the people are not distracted. At the heart of this uproar lies a simple question: Where did the confidential funds go, and how were they spent? The entire nation is now demanding accountability. First, for Congress to push through with its investigation into the OVP’s confidential funds. Lawmakers must resist any attempts to derail the inquiry and ensure that Duterte and her aides are held accountable. Pay particular attention to the SDO (special disbursement officers). Second, we Filipino voters are demanding transparency. We will make our voices heard in the midterm elections in May. We will seize this opportunity to elect leaders committed to transparency and reform. Sara Duterte’s actions serve as a cautionary tale: Misplaced trust can embolden leaders to trample on the principles of good governance. That’s why we remind all public officials that their ultimate loyalty should be to us the people, not their inner circle. The Vice President may think she can deflect attention with threats and drama, but the Filipino people are watching. And we demand answers: Ibabalik ba ang nilustay na confidential funds? Though VP Sara tried to downplay her “kill threat”, claiming they weren’t a direct threat due to their conditional phrasing, the implications are very alarming and sets a dangerous precedent of political intimidation in our country’s governance. This is not mere bravado but a troubling sign of the volatility pervading Philippine politics today. At the same time, it raises serious questions about her judgment and fitness for office. The ramifications are stark; her threats foster a hostile atmosphere that may cripple effective governance and collaborative policymaking. If Duterte feels emboldened to threaten high-ranking officials, it may stifle honest debate and cooperation essential for solving critical issues, from healthcare to economic recovery. As calls for impeachment grow, propelled by concerns over her mental stability and allegations of misusing public funds, we must ask ourselves: Should the people still trust her who shouts invectives, incites fear rather than promote dialogue? The vice presidency position demands seriousness and decorum, not personal attacks or threats against rivals. Each time a leader resorts to intimidation over constructive engagement, they erode public trust and degrade civil discourse. Subscribe to our daily newsletter By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy . In conclusion, it is time to demand more from our leaders: accountability, transparency, and respect for public service. We must move away from unjustified threats and embrace responsible governance. This moment should serve as a wake-up call, reminding us that democracy flourishes through active participation and accountability by the governed. The integrity of our political landscape hinges on this moment; let us step forward with purpose.BEIRUT (AP) — Israel's military launched airstrikes across Lebanon on Monday, unleashing explosions throughout the country and killing at least 31 while Israeli leaders appeared to be closing in on a negotiated ceasefire with the Hezbollah militant group. Israeli strikes hit commercial and residential buildings in Beirut as well as in the port city of Tyre. Military officials said they targeted areas known as Hezbollah strongholds. They issued evacuation orders for Beirut's southern suburbs, and strikes landed across the city, including meters from a Lebanese police base and the city's largest public park. The barrage came as officials indicated they were nearing agreement on a ceasefire, while Israeli Prime Minister Benjamin Netanyahu 's Security Cabinet prepared to discuss an offer on the table. Massive explosions lit up Lebanon's skies with flashes of orange, sending towering plumes of smoke into the air as Israeli airstrikes pounded Beirut’s southern suburbs Monday. The blasts damaged buildings and left shattered glass and debris scattered across nearby streets. No casualties were reported after many residents fled the targeted sites. Some of the strikes landed close to central Beirut and near Christian neighborhoods and other targets where Israel had issued evacuation warnings, including in Tyre and Nabatiyeh province. Israeli airstrikes also hit the northeast Baalbek-Hermel region without warning. Lebanon’s Health Ministry said Monday that 26 people were killed in southern Lebanon, four in the eastern Baalbek-Hermel province and one in Choueifat, a neighborhood in Beirut's southern suburbs that was not subjected to evacuation warnings on Monday. The deaths brought the total toll to 3,768 killed in Lebanon throughout 13 months of war between Israel and Hezbollah and nearly two months since Israel launched its ground invasion. Many of those killed since the start of the war between Israel and Hezbollah have been civilians , and health officials said some of the recovered bodies were so severely damaged that DNA testing would be required to confirm their identities. Israel says it has killed more than 2,000 Hezbollah members. Lebanon's Health Ministry says the war has displaced 1.2 million people. Israeli ground forces invaded southern Lebanon in early October, meeting heavy resistance in a narrow strip of land along the border. The military had previously exchanged attacks across the border with Hezbollah, an Iran-backed militant group that began firing rockets into Israel the day after the war in Gaza began last year. Lebanese politicians have decried the ongoing airstrikes and said they are impeding U.S.-led ceasefire negotiations. The country's deputy parliament speaker accused Israel of ramping up its bombardment in order to pressure Lebanon to make concessions in indirect ceasefire negotiations with Hezbollah. Elias Bousaab, an ally of the militant group, said Monday that the pressure has increased because “we are close to the hour that is decisive regarding reaching a ceasefire.” Israeli officials voiced similar optimism Monday about prospects for a ceasefire. Mike Herzog, the country's ambassador to Washington, earlier in the day told Israeli Army Radio that several points had yet to be finalized. Though any deal would require agreement from the government, Herzog said Israel and Hezbollah were “close to a deal." “It can happen within days,” he said. Israeli officials have said the sides are close to an agreement that would include withdrawal of Israeli forces from southern Lebanon and a pullback of Hezbollah fighters from the Israeli border. But several sticking points remain. Two Israeli officials told The Associated Press that Netanyahu’s security Cabinet had scheduled a meeting for Tuesday, but they said it remained unclear whether the Cabinet would vote to approve the deal. The officials spoke on condition of anonymity because they were discussing internal deliberations. Danny Danon, Israel’s U.N. ambassador, told reporters Monday that he expected a ceasefire agreement with Hezbollah to have stages and to be discussed by leaders Monday or Tuesday. Still, he warned, “it’s not going to happen overnight.” After previous hopes for a ceasefire were dashed, U.S. officials cautioned that negotiations were not yet complete and noted that there could be last-minute hitches that either delay or destroy an agreement. "Nothing is done until everything is done," White House national security spokesman John Kirby said Monday. The proposal under discussion to end the fighting calls for an initial two-month ceasefire during which Israeli forces would withdraw from Lebanon and Hezbollah would end its armed presence along the southern border south of the Litani River. The withdrawals would be accompanied by an influx of thousands more Lebanese army troops, who have been largely sidelined in the war, to patrol the border area along with an existing U.N. peacekeeping force . Western diplomats and Israeli officials said Israel is demanding the right to strike in Lebanon if it believes Hezbollah is violating the terms. The Lebanese government has said that such an arrangement would authorize violations of the country's sovereignty. A ceasefire could mark a step toward ending the regionwide war that ballooned after Hamas-led militants stormed into southern Israel on Oct. 7, 2023, killing some 1,200 people, mostly civilians, and abducting another 250 . The lack of a ceasefire has emerged as a political liability for Israeli leaders including Netanyahu, particularly while 60,000 Israelis remain away from their homes in the country's north after more than a year of cross-border violence. Hezbollah rockets have reached as far south into Israel as Tel Aviv. At least 75 people have been killed, more than half of them civilians. More than 50 Israeli soldiers died fighting in the ground offensive in Lebanon. The Israeli military said about 250 projectiles were fired Sunday, with some intercepted. A ceasefire between Israel and Hezbollah, the strongest of Iran’s armed proxies , is expected to significantly calm regional tensions that have led to fears of a direct, all-out war between Israel and Iran. It’s not clear how the ceasefire will affect the Israel-Hamas war in Gaza. Hezbollah had long insisted that it would not agree to a ceasefire until the war in Gaza ends, but it dropped that condition. A top Hamas official in Lebanon said the Palestinian militant group would support a ceasefire between its Lebanese ally Hezbollah and Israel, despite Hezbollah’s previous promises to stop the fighting in Lebanon only if the war in Gaza ends. “Any announcement of a ceasefire is welcome. Hezbollah has stood by our people and made significant sacrifices,” Osama Hamdan of Hamas' political wing told the Lebanese broadcaster Al-Mayadeen, which is seen as politically allied with Hezbollah. While the ceasefire proposal is expected to be approved if Netanyahu brings it to a vote in his security Cabinet, one hard-line member, National Security Minister Itamar Ben-Gvir, said he would oppose it. He said on X that a deal with Lebanon would be a “big mistake” and a “missed historic opportunity to eradicate Hezbollah.” If the ceasefire talks fail, Jordanian Foreign Minister Ayman Safadi said, “it will mean more destruction and more and more animosity and more dehumanization and more hatred and more bitterness.” Speaking at a G7 meeting in Fiuggi, Italy, the last summit of its kind before U.S. President Joe Biden leaves office, Safadi said such a failure "will doom the future of the region to more conflict and more killing and more destruction.” Federman reported from Jerusalem and Metz from Rabat, Morocco. Associated Press writers Edith M. Lederer at the United Nations, Nicole Winfield in Fiuggi, Italy, and Aamer Madhani in Washington contributed to this report. Find more of AP’s war coverage at https://apnews.com/hub/israel-hamas-war

FROM DUNGEON TO DAYLIGHT

AP Business SummaryBrief at 6:15 p.m. ESTRepublican Mariannette Miller-Meeks wins reelection to U.S. House in Iowa's 1st Congressional District

New plan to punish tech giants over news sharing

Published 8:12 am Saturday, November 23, 2024 By Sabrina Simms Robertson NATCHEZ — Natchez Early College Academy senior Zelik Q. Patten has been selected to be a member of the esteemed National Society of High School Scholars. The Society recognizes top scholars who have demonstrated outstanding leadership, scholarship and community commitment. Patten plans to graduate from high school this summer with both his high school diploma and an Associate’s Degree from Copiah Lincoln Community College. He then plans to pursue a four-year degree in computer science. While not fully decided on a college, Patten said Louisiana State University is on top of his list. Formed in 2002 by James W. Lewis and Claes Nobel, member of the family that established the Nobel Prizes, the National Society of High School Scholars recognizes academic excellence at the high school level and helps to advance the goals and aspirations of high-achieving students through unique learning experiences, scholarships, internships, international study, and peer networks. Currently, there are more than 1,700,000 members in over 170 countries. “On behalf of NSHSS and our co-founder Claes Nobel, a member of the family that established the Nobel Prizes, I am honored to recognize the hard work, passion and commitment that Zelik has demonstrated to achieve this exceptional level of academic excellence,” said NSHSS Co-founder and President James W. Lewis. “Zelik is now a member of a unique community of scholars — a community that represents our very best hope for the future. “We are proud to provide lifetime membership to young scholars to support their growth and development. We help students like Zelik build on their academic success by connecting them with learning experiences and resources to help prepare them for college and meaningful careers.” NSHSS members automatically become lifetime members at the time of their initial membership. Each step along the way from high school to college to career, NSHSS connects outstanding young scholars with the resources they need to develop their strengths and pursue their passions. Patten sees himself starting a business one day advancing new technologies such as robot vacuums, he said. “I’ve always been good with technology and wanted to deal with stuff like that, but my cousins in that field influenced me. They encouraged me,” Patten said. Patten is also a member of the National Beta Club, which in February traveled to a convention in Biloxi. He and his Beta Club team placed in a robotics competition where he programmed and helped build a robot, he said. “All of us worked on building it and putting it together but while they were building the actual body I was working on the technical part of it.” Patten’s biggest role models are his parents Aaron and Linda Patten and his late grandmothers, Cynthia Barfield and Ida Bridgeman, he said. “My grandma used to call me a walking book,” he said. “It gave me motivation to keep doing well to make them proud.” Linda Patten said Zelik’s two older brothers also challenged him to do well in school. “When he was younger he would say he wanted to challenge his brothers,” she said. “They’d received full academic scholarships and one graduated early and he wanted to do better than them.” Patten said he scored a 31 super score on his last ACT with a 36 in reading, his best subject area, he said. “Reading has always been the easiest for me. I like to read a lot of mythology, like Percy Jackson and things like that,” Patten said. His other hobbies include basketball and playing video games, he said. For more information about the National Society of High School Scholars, visit www.nshss.org .WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") WINT , a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. "The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities," said Craig Fraser, Chairman and CEO. "With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements," Mr. Fraser added. "Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization." Key Business Updates Announced positive Phase 2b topline clinical results with istaroxime significantly improving cardiac function and blood pressure in heart failure patients with early cardiogenic shock. The study met its primary endpoint in significantly improving systolic blood pressure over six hours (SBP AUC) for the combined Part A and Part B SEISMiC istaroxime group compared to placebo as well as for SEISMiC Part B alone. The improvements in SBP AUC at 24 hours were also significantly increased by istaroxime and the improvements were sustained through 96 hours of measurement. Cardiac output (the amount of blood pumped by the heart over a minute) and filling pressures in the heart significantly improved as did measured kidney function. Heart failure severity as assessed by the NYHA classification decreased significantly up to 72 hours compared to placebo. A favorable safety and tolerability profile, including risk for cardiac arrythmias, was also observed. The clinical study data was presented in a late-breaker session at the Heart Failure Society of America conference and the Company reviewed the clinical results along with the program strategy and plans at a virtual Investor Meeting which has been posted to the Company website. Completed two private placements in July 2024 for aggregate proceeds of approximately $13.9 million, which consisted of approximately $4.4 million of new funding (with $2.3 million of net proceeds) and a $9.5 million payment through the full cancellation and extinguishment of certain holders outstanding senior notes, including secured notes, and shares of the Company's Series B Convertible Preferred Stock. Entered into a Common Stock Purchase Agreement with an equity line investor, whereby the Company has the right, but not the obligation, to sell such investor, and, subject to limited exceptions, the investor is obligated to purchase for up to $35 million of newly issued shares of the Company's common stock. Announced initiation of the SEISMiC C study of istaroxime in SCAI Stage C cardiogenic shock to complete Phase 2b and advance the transition to Phase 3. This is a global trial including sites in the U.S., Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care with inotropes and/or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for 6 hours and based on the patient's condition, the ability to remove standard of care therapies while on istaroxime will also be assessed. The primary endpoint of the study is assessment of systolic blood pressure (SBP) profile over the first 6 hours of treatment. Expanded patent estate with new patents with istaroxime in cardiogenic shock and acute heart failure. Cardiogenic shock national phase filings were completed for patent applications around the world, including in the United States, Germany, France, Italy, Japan and China. A patent was issued for istaroxime for Japan entitled, "Istaroxime-containing intravenous formulation for the treatment of heart failure and it has been accorded Patent No. 7560134. A patent was issued for istaroxime for Hong Kong, and it is entitled, "Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF)." The claims are directed formulations comprising istaroxime, pharmaceutically acceptable salts thereof, and methods of use, alone, or in combination with other agents useful for the treatment and management of acute heart failure. Select Third Quarter 2024 Financial Results For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company's business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff ("Staff") of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q ("Form 10-Q") for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company's Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree's portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: the Company's ability to secure significant additional capital as and when needed; the Company's ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates, including preclinical oncology candidates; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates, if approved; the Company's ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People's Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company's ability to access the capital markets. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov . Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis ecurtis@windtreetx.com WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES Consolidated Balance Sheets (in thousands, except share and per share data) September 30, 2024 December 31, 2023 (Unaudited) ASSETS Current Assets: Cash and cash equivalents $ 2,300 $ 4,319 Prepaid expenses and other current assets 1,628 1,060 Total current assets 3,928 5,379 Property and equipment, net 128 183 Restricted cash 9 150 Operating lease right-of-use assets 1,133 1,444 Intangible assets 25,250 25,250 Total assets $ 30,448 $ 32,406 LIABILITIES, MEZZANINE EQUITY & STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 2,054 $ 809 Accrued expenses 1,650 1,618 Operating lease liabilities - current portion 468 436 ELOC commitment note payable 317 - Derivative liability - ELOC commitment note 347 - Common stock warrant liability 8,621 - Loans payable 444 233 Other current liabilities 525 900 Total current liabilities 14,426 3,996 Operating lease liabilities - non-current portion 784 1,161 Restructured debt liability - contingent milestone payments - 15,000 Other liabilities 3,800 3,800 Deferred tax liabilities 4,887 5,058 Total liabilities 23,897 29,015 Mezzanine Equity: Series C redeemable preferred stock, $0.001 par value; 18,820 and 0 shares authorized; 15,719 and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 2,142 - Series B redeemable preferred stock, $0.001 par value; 5,500 and 0 shares authorized; 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively - - Total mezzanine equity 2,142 - Stockholders' Equity: Preferred stock, $0.001 par value; 4,975,680 and 5,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively - - Common stock, $0.001 par value; 120,000,000 shares authorized; 2,340,429 and 333,145 shares issued at September 30, 2024 and December 31, 2023, respectively; 2,340,428 and 333,144 shares outstanding at September 30, 2024 and December 31, 2023, respectively 2 - Additional paid-in capital 856,267 851,268 Accumulated deficit (848,806 ) (844,823 ) Treasury stock (at cost); 1 share (3,054 ) (3,054 ) Total stockholders' equity 4,409 3,391 Total liabilities, mezzanine equity & stockholders' equity $ 30,448 $ 32,406 WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES Consolidated Statements of Operations (in thousands, except per share data) Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Expenses: Research and development $ 1,968 $ 2,110 $ 14,084 $ 5,288 General and administrative 2,773 2,580 6,514 7,292 Loss on impairment of goodwill - - - 3,058 Total operating expenses 4,741 4,690 20,598 15,638 Operating loss (4,741 ) (4,690 ) (20,598 ) (15,638 ) Other income (expense): Gain on debt extinguishment 71 - 14,591 - Change in fair value of common stock warrant liability 2,166 - 2,166 - Interest income 12 112 62 264 Interest expense (51 ) (13 ) (174 ) (38 ) Other (expense) income, net (446 ) 166 (530 ) 275 Total other income, net 1,752 265 16,115 501 Loss before income taxes (2,989 ) (4,425 ) (4,483 ) (15,137 ) Income tax benefit (expense) 240 - (71 ) - Net loss $ (2,749 ) $ (4,425 ) $ (4,554 ) $ (15,137 ) Extinguishment of Series B Preferred Stock 572 - 572 - Deemed dividend on Series C Preferred Stock (1,573 ) - (1,573 ) - Net loss attributable to common stockholders $ (3,750 ) $ (4,425 ) $ (5,555 ) $ (15,137 ) Net loss per share attributable to common stockholders Basic and diluted $ (4.23 ) $ (15.47 ) $ (8.64 ) $ (80.95 ) Weighted average number of common shares outstanding Basic and diluted 887 286 643 187 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Zimmer Biomet Receives FDA Approval for Oxford® Cementless Partial Knee, Only Cementless Partial Knee Replacement Implant in the U.S.

Has Bill Belichick closed the door on NFL victories record? There's still time to evaluateFDA tries last-ditch move to slash nicotine levels in cigarettes

The Hershey Company (NYSE:HSY) Shares Sold by Banque Cantonale Vaudoise

Police Say They Have Their Hands on the Alleged Healthcare CEO Killer’s Notebook

Commissioner Goodell says no change to NFL’s relationship with Jay-Z amid rape allegationsMeta said it is “99% of the way there” in solving an ongoing social media blackout with its apps. On Wednesday at around 6pm, thousands of social media users in parts of the UK reported an outage with Facebook, Instagram and WhatsApp. The social media giant reported that a “technical issue” had left users unable to access its services. DownDetector, a website that monitors social media outages, says the three cities hit worst by the outage were London, Manchester and Glasgow. Other major cities hit hard by the blackout were Cardiff, Nottingham and Birmingham. By around 10pm on Wednesday, DownDetector UK said there had been 23,445 reports of Facebook outages, 11,466 Instagram outages and 18,646 on WhatsApp across Britain. In an update issued at 10.26pm on X, Meta said the problem was now nearly resolved. A spokesperson said: “Thanks for bearing with us! We’re 99% of the way there – just doing some last checks. “We apologise to those who’ve been affected by the outage.” Other parts of the world affected include Europe, Asia, South America and Australia, according to DownTracker. To find out if your area is affected, visit: downdetector.co.uk/status/facebook/map .InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Digital Ally, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-QDonald Trump used his image as a successful New York businessman to become a celebrity, a reality television star and eventually the president. Now he will get to revel in one of the most visible symbols of success in the city when he rings the opening bell of the New York Stock Exchange on Thursday as he’s also named Time Magazine’s Person of the Year. Trump is expected to be on Wall Street to mark the ceremonial start of the day’s trading, according to four people with knowledge of his plans. He will also be announced Thursday as Time’s 2024 Person of the Year, according to a person familiar with the selection. The people who confirmed the stock exchange appearance and Time award were not authorized to discuss the matter publicly and spoke to The Associated Press on condition of anonymity. It will be a notable moment of twin recognitions for Trump, a born-and-bred New Yorker who at times has treated the stock market as a measure of public approval and has long-prized signifiers of his success in New York’s business world and his appearances on the covers of magazines — especially Time. Trump was named the magazine’s Person of the Year in 2016, when he was first elected to the White House. He had already been listed as a finalist for this year’s award alongside Vice President Kamala Harris, X owner Elon Musk, Israeli Prime Minister Benjamin Netanyahu and Kate, the Princess of Wales. Time declined to confirm the selection ahead of Thursday morning’s announcement. “Time does not comment on its annual choice for Person of the Year prior to publication,” a spokesperson for the magazine said Wednesday. The ringing of the bell is a powerful symbol of U.S. capitalism — and a good New York photo opportunity at that. Despite his decades as a New York businessman, Trump has never done it before. It was unclear whether Trump, a Republican, would meet with New York’s embattled mayor, Democrat Eric Adams, who has warmed to Trump and has not ruled out changing his political party. Adams has been charged with federal corruption crimes and accused of selling influence to foreign nationals; he has denied wrongdoing. Trump himself was once a symbol of New York, but he gave up living full-time in his namesake Trump Tower in Manhattan and moved to Florida after leaving the White House. CNN first reported Wednesday Trump’s visit to the stock exchange and Politico reported that Trump was expected to be unveiled as Time’s Person of the Year. The stock exchange regularly invites celebrities and business leaders to participate in the ceremonial opening and closing of trading. During Trump’s first term, his wife, Melania Trump, rang the bell to promote her “Be Best” initiative on children’s well-being. Last year, Time CEO Jessica Sibley rang the opening bell to unveil the magazine’s 2023 Person of the Year: Taylor Swift. After the Nov. 5 election, the S&P 500 rallied 2.5% for its best day in nearly two years. The Dow Jones Industrial Average surged 1,508 points, or 3.6%, while the Nasdaq composite jumped 3%. All three indexes topped records they had set in recent weeks. The U.S. stock market has historically tended to rise regardless of which party wins the White House, with Democrats scoring bigger average gains since 1945. But Republican control could mean big shifts in the winning and losing industries underneath the surface, and investors are adding to bets built earlier on what the higher tariffs, lower tax rates and lighter regulation that Trump favors will mean. Trump has long courted the business community based on his own status as a wealthy real estate developer who gained additional fame as the star of the TV show “The Apprentice” in which competitors tried to impress him with their business skills. He won the election in part by tapping into Americans’ deep anxieties about an economy that seemed unable to meet the needs of the middle class. The larger business community has applauded his promises to reduce corporate taxes and cut regulations. But there are also concerns about his stated plans to impose broad tariffs and possibly target companies that he sees as not aligning with his own political interests. Trump spends the bulk of his time at his Florida home but was in New York for weeks this spring during his hush money trial there. He was convicted, but his lawyers are pushing for the case to be thrown out in light of his election. While he spent hours in a Manhattan courthouse every day during his criminal trial, Trump took his presidential campaign to the streets of the heavily Democratic city, holding a rally in the Bronx and popping up at settings for working-class New Yorkers: a bodega, a construction site and a firehouse. Trump returned to the city in September to meet with Ukrainian President Volodymyr Zelenskyy at his Manhattan tower and again in the final stretch of the presidential campaign when he held a rally at Madison Square Garden that drew immediate blowback as speakers made rude and racist insults and incendiary remarks. At the stock exchange, the ringing of the bell has been a tradition since the 1800s. The first guest to do it was a 10-year-old boy named Leonard Ross, in 1956, who won a quiz show answering questions about the stock market. Many times, companies listing on the exchange would ring the bell at 9:30 a.m. to commemorate their initial offerings as trading began. But the appearances have become an important marker of culture and politics — something that Trump hopes to seize as he’s promised historic levels of economic growth. The anti-apartheid advocate and South African President Nelson Mandela rang the bell, as has Hollywood star Sylvester Stallone with his castmates from the film “The Expendables.” So, too, have the actors Robert Downey Jr. and Jeremy Renner for an “Avengers” movie and the Olympians Michael Phelps and Natalie Coughlin. In 1985, Ronald Reagan became the first sitting U.S. president to ring the bell. “With tax reform and budget control, our economy will be free to expand to its full potential, driving the bears back into permanent hibernation,” Reagan said at the time. “We’re going to turn the bull loose.” The crowd of traders on the floor chanted, “Ronnie! Ronnie! Ronnie!” The Dow Jones Industrial Average climbed in 1985 and 1986, but it suffered a decline in October 1987 in an event known as “Black Monday.” ___ Long reported from Washington. Associated Press writer Josh Boak in Washington contributed to this report. U.S. stock indexes got back to climbing on Wednesday after Donald Trump used his image as a successful New York The House on Wednesday passed a $895 billion measure that U.S. stock indexes drifted lower Tuesday in the runup to

DENVER--(BUSINESS WIRE)--Dec 13, 2024-- The Western Union Company (NYSE: WU) announced today that its Board of Directors approved a new $1 billion authorization for the Company to repurchase its common stock and declared a quarterly cash dividend of $0.235 per common share. The dividend will be payable December 31, 2024, to stockholders of record at the close of business on December 23, 2024. “We remain committed to returning capital to our shareholders with our disciplined approach focused on driving long-term shareholder value through both dividends and stock repurchases and today’s announcements allows us the flexibility to continue to do that,” said Devin McGranahan, President and Chief Executive Officer. Repurchases may be made at management’s discretion through open-market transactions, privately negotiated transactions, tender offers, Rule 10b5-1 plans, or by other means. The amount and timing of any repurchases made under the share repurchase program will depend on a variety of factors, including market conditions, share price, legal requirements, and other factors. The program does not have a set expiration date and may be suspended, modified, or discontinued at any time without prior notice. Safe Harbor Compliance Statement for Forward-Looking Statements This press release contains certain statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict. Actual outcomes and results may differ materially from those expressed in, or implied by, our forward-looking statements. Words such as “expects,” “intends,” “targets,” “anticipates,” “believes,” “estimates,” “guides,” “provides guidance,” “provides outlook,” “projects,” “designed to,” and other similar expressions or future or conditional verbs such as “may,” “will,” “should,” “would,” “could,” and “might” are intended to identify such forward-looking statements. Readers of this press release of The Western Union Company (the “Company,” “Western Union,” “we,” “our,” or “us”) should not rely solely on the forward-looking statements and should consider all uncertainties and risks discussed in the Risk Factors section and throughout the Annual Report on Form 10-K for the year ended December 31, 2023. The statements are only as of the date they are made, and the Company undertakes no obligation to update any forward-looking statement. Possible events or factors that could cause results or performance to differ materially from those expressed in our forward-looking statements include the following: (i) events related to our business and industry, such as: changes in general economic conditions and economic conditions in the regions and industries in which we operate, including global economic downturns and trade disruptions, or significantly slower growth or declines in the money transfer, payment service, and other markets in which we operate, including downturns or declines related to interruptions in migration patterns or other events, such as public health emergencies, epidemics, or pandemics, civil unrest, war, terrorism, natural disasters, or non-performance by our banks, lenders, insurers, or other financial services providers; failure to compete effectively in the money transfer and payment service industry, including among other things, with respect to price or customer experience, with global and niche or corridor money transfer providers, banks and other money transfer and payment service providers, including digital, mobile and internet-based services, card associations, and card-based payment providers, and with digital currencies and related exchanges and protocols, and other innovations in technology and business models; geopolitical tensions, political conditions and related actions, including trade restrictions and government sanctions, which may adversely affect our business and economic conditions as a whole, including interruptions of United States or other government relations with countries in which we have or are implementing significant business relationships with agents, clients, or other partners; deterioration in customer confidence in our business, or in money transfer and payment service providers generally; failure to maintain our agent network and business relationships under terms consistent with or more advantageous to us than those currently in place; our ability to adopt new technology and develop and gain market acceptance of new and enhanced services in response to changing industry and consumer needs or trends; mergers, acquisitions, and the integration of acquired businesses and technologies into our Company, divestitures, and the failure to realize anticipated financial benefits from these transactions, and events requiring us to write down our goodwill; decisions to change our business mix; changes in, and failure to manage effectively, exposure to foreign exchange rates, including the impact of the regulation of foreign exchange spreads on money transfers; changes in tax laws, or their interpretation, any subsequent regulation, and unfavorable resolution of tax contingencies; any material breach of security, including cybersecurity, or safeguards of or interruptions in any of our systems or those of our vendors or other third parties; cessation of or defects in various services provided to us by third-party vendors; our ability to realize the anticipated benefits from restructuring-related initiatives, which may include decisions to downsize or to transition operating activities from one location to another, and to minimize any disruptions in our workforce that may result from those initiatives; our ability to attract and retain qualified key employees and to manage our workforce successfully; failure to manage credit and fraud risks presented by our agents, clients, and consumers; adverse rating actions by credit rating agencies; our ability to protect our trademarks, patents, copyrights, and other intellectual property rights, and to defend ourselves against potential intellectual property infringement claims; material changes in the market value or liquidity of securities that we hold; restrictions imposed by our debt obligations; (ii) events related to our regulatory and litigation environment, such as: liabilities or loss of business resulting from a failure by us, our agents, or their subagents to comply with laws and regulations and regulatory or judicial interpretations thereof, including laws and regulations designed to protect consumers, or detect and prevent money laundering, terrorist financing, fraud, and other illicit activity; increased costs or loss of business due to regulatory initiatives and changes in laws, regulations and industry practices and standards, including changes in interpretations, in the United States and abroad, affecting us, our agents or their subagents, or the banks with which we or our agents maintain bank accounts needed to provide our services, including related to anti-money laundering regulations, anti-fraud measures, our licensing arrangements, customer due diligence, agent and subagent due diligence, registration and monitoring requirements, consumer protection requirements, remittances, immigration, and sustainability reporting including climate-related reporting; liabilities, increased costs or loss of business and unanticipated developments resulting from governmental investigations and consent agreements with, or investigations or enforcement actions by regulators and other government authorities; liabilities resulting from litigation, including class-action lawsuits and similar matters, and regulatory enforcement actions, including costs, expenses, settlements, and judgments; failure to comply with regulations and evolving industry standards regarding consumer privacy, data use, the transfer of personal data between jurisdictions, and information security, failure to comply with the Dodd-Frank Wall Street Reform and Consumer Protection Act, as well as regulations issued pursuant to it and the actions of the Consumer Financial Protection Bureau and similar legislation and regulations enacted by other governmental authorities in the United States and abroad related to consumer protection; effects of unclaimed property laws or their interpretation or the enforcement thereof; failure to maintain sufficient amounts or types of regulatory capital or other restrictions on the use of our working capital to meet the changing requirements of our regulators worldwide; changes in accounting standards, rules and interpretations, or industry standards affecting our business; and (iii) other events, such as catastrophic events and management’s ability to identify and manage these and other risks. About Western Union The Western Union Company (NYSE: WU) is committed to helping people around the world who aspire to build financial futures for themselves, their loved ones and their communities. Our leading cross-border, cross-currency money movement, payments and digital financial services empower consumers, businesses, financial institutions and governments—across more than 200 countries and territories and nearly 130 currencies—to connect with billions of bank accounts, millions of digital wallets and cards, and a global footprint of hundreds of thousands of retail locations. Our goal is to offer accessible financial services that help people and communities prosper. For more information, visit www.westernunion.com . WU-G View source version on businesswire.com : https://www.businesswire.com/news/home/20241213394701/en/ CONTACT: Media Relations: Brad Jones media@westernunion.comInvestor Relations: Tom Hadley WesternUnion.IR@westernunion.com KEYWORD: COLORADO UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SOFTWARE PERSONAL FINANCE PAYMENTS FINANCE BANKING PROFESSIONAL SERVICES TECHNOLOGY FINTECH SOURCE: The Western Union Company Copyright Business Wire 2024. PUB: 12/13/2024 04:05 PM/DISC: 12/13/2024 04:04 PM http://www.businesswire.com/news/home/20241213394701/enIfedi starts at left tackle for Browns in prime-time matchup against AFC North-leading Steelers

Swiss National Bank lowered its holdings in Medpace Holdings, Inc. ( NASDAQ:MEDP – Free Report ) by 0.6% during the third quarter, HoldingsChannel.com reports. The fund owned 51,500 shares of the company’s stock after selling 300 shares during the period. Swiss National Bank’s holdings in Medpace were worth $17,191,000 as of its most recent filing with the Securities & Exchange Commission. A number of other large investors have also recently bought and sold shares of the business. Westwind Capital raised its holdings in Medpace by 800.1% during the second quarter. Westwind Capital now owns 380,929 shares of the company’s stock worth $156,886,000 after purchasing an additional 338,610 shares in the last quarter. Clearbridge Investments LLC lifted its stake in shares of Medpace by 55.1% in the 2nd quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock valued at $166,343,000 after purchasing an additional 143,481 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Medpace by 38.3% in the 2nd quarter. Renaissance Technologies LLC now owns 443,588 shares of the company’s stock valued at $182,692,000 after purchasing an additional 122,800 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Medpace by 62.3% in the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company’s stock valued at $127,941,000 after purchasing an additional 119,257 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Medpace by 1,028.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 116,683 shares of the company’s stock valued at $48,056,000 after purchasing an additional 106,343 shares during the last quarter. Institutional investors own 77.98% of the company’s stock. Analyst Upgrades and Downgrades A number of research analysts have weighed in on MEDP shares. Truist Financial cut their target price on shares of Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Robert W. Baird lowered shares of Medpace from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $413.00 to $349.00 in a research report on Wednesday, October 23rd. UBS Group lowered shares of Medpace from a “buy” rating to a “neutral” rating and cut their target price for the stock from $420.00 to $350.00 in a research report on Friday, September 27th. TD Cowen cut their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Finally, Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Medpace currently has a consensus rating of “Hold” and a consensus target price of $380.00. Medpace Stock Performance NASDAQ:MEDP opened at $337.75 on Friday. The firm’s 50-day moving average is $340.42 and its 200-day moving average is $373.77. Medpace Holdings, Inc. has a 52-week low of $268.80 and a 52-week high of $459.77. The company has a market cap of $10.50 billion, a price-to-earnings ratio of 30.32, a PEG ratio of 1.74 and a beta of 1.37. Medpace ( NASDAQ:MEDP – Get Free Report ) last posted its earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. The business had revenue of $533.32 million for the quarter, compared to analysts’ expectations of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.22 earnings per share. Equities analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current year. About Medpace ( Free Report ) Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. Read More Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. ( NASDAQ:MEDP – Free Report ). Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter .Republican Mariannette Miller-Meeks wins reelection to U.S. House in Iowa's 1st Congressional DistrictWest Virginia is expected to bring Rich Rodriguez back to his home state as head coach of the Mountaineers, 17 years after he and the school had a messy breakup at the end of a successful and entertaining seven-season run, a source close to the negotiations told The Athletic . Rodriguez wrapped up his second season as head coach at Jacksonville State on Friday night, leading the Gamecocks to their first Conference USA title in a 52-14 victory against Western Kentucky on Friday night. Advertisement The 61-year-old native of Grant Town, W.Va., was one of the forefathers of up-tempo, spread-option offense, and he used it to turn West Virginia into a national contender with one of the most exciting teams in the country from 2001 to ‘07. Rodriguez went 60-26 with three double-digit victory seasons in his final three years. West Virginia was looking for a replacement for Neal Brown, who was fired after six seasons at the school, and found it in a reunion that seemed impossible when Rodriguez left the Mountaineers for Michigan in December 2007. Rodriguez’s departure came at an especially raw time for West Virginia, less than a month after the second-ranked Mountaineers were upset 13-9 in their regular-season finale by Pitt, costing the team a spot in the BCS Championship Game to play for a national title. Then he and the school got into an ugly legal fight over a $4 million buyout West Virginia said Rodriguez owed the school after agreeing to a new contract just four months earlier. A breach of contract lawsuit was filed by West Virginia and eventually settled with Michigan paying $2.5 million of the buyout and Rodriguez paying $1.5 million in installments. Rodriguez spent three rocky seasons at Michigan, going 3-9 in his first season and never really seeing eye-to-eye with the administration. As Rodriguez tried to flip the Wolverines’ roster to fit his style of play, Michigan made only marginal gains. He was fired after an embarrassing 52-14 loss to Mississippi State in the Gator Bowl, leaving Michigan with a 15-22 record. After taking a year off and working in TV, Rodriguez was hired by Arizona. It was a good fit, at least at first. The Wildcats went 26-14 in his first three seasons, winning 10 games and going to the Fiesta Bowl in 2014. The program slid back after that, and the end of his tenure was again tumultuous. A former administrative assistant accused Rodriguez of sexual harassment in a lawsuit that was eventually dismissed. After a three-month investigation by the school, Rodriguez, who admitted an extramarital affair, was fired. Advertisement Rodriguez spent the 2019 as offensive coordinator at Ole Miss and landed at Louisiana-Monroe as an assistant in 2021. Jacksonville State hired Rodriguez to help the program transition up to the Football Bowl Subdivision, and he delivered consecutive nine-win seasons. Now he returns to the scene of his greatest achievements in coaching, the hard feelings he left behind long gone as West Virginia searches for sustained success in the Big 12 after 13 years of mostly middling results. (Photo: Dave Hyatt / Special to the Gadsden Times / Imagn Images)

Electric Taxi Vertiport Market Future of Trends, CAGR and Value Insights for 2024-2031French President Emmanuel Macron accused Haiti's transitional council of being "total morons" for dismissing the country's prime minister, according to a video shot at the G20 summit in Brazil this week and shared on social media Thursday. In the footage, the French leader is speaking on the sidelines of the G20 in Rio with an individual accusing Macron and France of "being responsible for the situation in Haiti". Haiti's transitional council pushed out then-prime minister Garry Conille after just five months in office, a move Macron called "terrible" in the clip. "They're total morons," said Macron referring to the transitional body, adding, "they never should have dismissed him." Condemning the remarks, Haiti's Foreign Ministry said Thursday that French Ambassador Antoine Michon had been summoned following the "unacceptable comments." Haitian Minister of Foreign Affairs and Worship Jean-Victor Harvel Jean-Baptiste used the meeting to express "indignation" on behalf of the transitional council, which he said viewed the remarks as "an unfriendly and inappropriate gesture that must be rectified," according to a statement from the ministry. Haiti has suffered from decades of political instability. But in recent months, the Caribbean country has seen a surge in violence with gangs now controlling 80 percent of the capital, Port-au-Prince. The clip also shows the French president, who is on a multi-leg tour of Latin America with his most recent stop in Chile, blaming Haitians for "letting drug trafficking take over". "Quite frankly, it was the Haitians who killed Haiti," the French president said in the clip. Businessman Alix Didier Fils-Aime was sworn in as Haiti's new prime minister on November 12, promising to restore security in the crisis-wracked country. fff-lum/ekf/sjw/bfm/md